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nloaded fMuscle satellite cells (MuSCs) play a central role in muscle regeneration, but their quantity and function decline
with comorbidity of trauma, aging, and muscle diseases. Although transplantation of MuSCs in traumatically
injured muscle in the comorbid context of aging or pathology is a strategy to boost muscle regeneration, an
effective cell delivery strategy in these contexts has not been developed. We engineered a synthetic hydrogel-
based matrix with optimal mechanical, cell-adhesive, and protease-degradable properties that promotes MuSC
survival, proliferation, and differentiation. Furthermore, we establish a biomaterial-mediated cell delivery
strategy for treating muscle trauma, where intramuscular injections may not be applicable. Delivery of MuSCs
in the engineered matrix significantly improved in vivo cell survival, proliferation, and engraftment in nonirra-
diated and immunocompetent muscles of aged and dystrophic mice compared to collagen gels and cell-only
controls. This platform may be suitable for treating craniofacial and limb muscle trauma, as well as post-
operative wounds of elderly and dystrophic patients.rom
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Skeletal muscle generates force to enable movement and support vital
functions such as deglutition and respiration. Although healthy muscle
exhibits remarkable adaptive and regenerative capacities, its function
declines with comorbidity of severe physical trauma, aging, and disease
(1–5). Inadequate regeneration of muscle begets debilitating con-
sequences, including long-term disabilities and reduced quality of life
(5–7). Current clinical interventions for muscle trauma entail muscle
flap transfer and surgical suture, but these treatments alone do not com-
pletely regenerate the damagedmuscle (3, 8–10). Clinical strategies that
effectively regenerate traumatically injured muscle in comorbidity with
aging and muscle pathology currently do not exist and are in great crit-
ical need.
Muscle satellite cells (MuSCs) are muscle-resident stem cells that
play an indispensable role in myogenesis, and their function centrally
dictates the regenerative capacity of muscle in the context of injury,
aging, and disease (11–15). Upon injury, quiescent MuSCs (Pax7+/
MyoD−) activate to give rise to proliferating myoblasts (Pax7+/MyoD+)
that undergo myogenic differentiation or fusion with existing myofibers
(1, 2). Asymmetric division of MuSCs maintains muscle homeostasis,
where this process is critical for regeneration of damaged myofibers
and repopulation of the stem cell reservoir through self-renewal for en-
suing regenerative needs (16–18). However, the intrinsic function and
quantity of MuSCs decline with aging (13, 19–23) and neuromuscular
diseases, such as Duchenne muscular dystrophy (DMD) (14, 15), andcontribute to the diminished regenerative potential of muscle. For exam-
ple, onemechanism that causes age-associated decline inMuSC function
and number is thatMuSCs lose the ability to asymmetrically divide from
abnormal Janus kinase–signal transducer and activator of transcription
and p38 signaling and undergo cellular senescence from elevated
p16INK4A (19, 21, 22). In DMD, dystrophin-deficient MuSCs exhibit im-
paired mitosis and loss of asymmetric division (14). Dysregulation of
MuSC function ultimately results in depletion of the MuSC reservoir
and defective muscle regenerative potential. The regenerative potential
further diminishes upon traumatic muscle injuries, such as bone-muscle
polytrauma, laceration, crush, and severe burn, where MuSCs undergo
concurrent activation and cell death (24–27).Althoughapproaches aimed
to replenish functional MuSCs in traumatically injured muscles in the
comorbid context of aging or chronic pathology may be an effective
strategy to boost degenerating muscle function, successful and translat-
able approaches to transplant MuSCs in traumatically injured aged or
pathologic muscles have not yet been developed.
Transplantation of MuSCs into injured, aging, and dystrophic
muscles results in engraftment and repopulation of the quiescentMuSC
pool (28–31). This strategy has significant potential for administer-
ing MuSCs as a cellular source for stem cell therapy for muscle injury,
sarcopenia, and muscular dystrophy. However, previous proof-of-
principle transplantation experiments have been conducted on skeletal
muscles that were cardiotoxin/notexin/BaCl2-injured, irradiated,
and/or immunodeficient, limiting their clinical translatability (28–31).
Furthermore, direct delivery of cells via injection has challenges at the
translational level, including massive donor cell death and cellular dis-
persion, severely limiting its therapeutic potential (32, 33). Only 1 to
20% of the transplanted cells survive in the host tissue due to the harsh
inflammatory environment, and the surviving donor cells exhibit
limited function (32, 33). Note that cell delivery via injection may not
always be applicable in traumatic injuries, where the structural integrity
of the muscle is often severely compromised to receive an injection.
To address these limitations, naturally derived biomaterials, such as
decellularized matrix, collagen, hyaluronic acid, fibrin, and alginate1 of 14
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 hydrogels, have been used to facilitate the delivery of myogenic cells
to the muscle (34–45). However, naturally derived materials are sus-
ceptible to lot-to-lot variability, potential pathogen transfer, anddifficul-
ty in controlling the material’s microstructure, mechanical properties,
and degradability; these limitations hinder their translatability, wide ap-
plicability, and systematic investigation ofmaterial-MuSC interactions to
improve engraftment efficacy (46). Furthermore, previous studies used
nonquiescent myoblasts that had been expanded in vitro, and thus,
knowledge on how the biochemical and biophysical properties of these
materials affect quiescent MuSC activities is limited. Synthetic matrices,
on the other hand, offer a promising alternative to natural biomaterials,
as biochemical and biophysical properties can be modularly altered to
investigate three-dimensional (3D) cellular functions in a systematic
manner. To that end, we hypothesized that a synthetic biofunctional hy-
drogel, which presents promyogenic cell adhesive peptides and defined
mechanical, transport, and on-demand degradation properties, could be
engineered to support MuSC activities and serve as a delivery vehicle to
enhance the engraftment of donor cells in traumatically injured, nonir-
radiated, and immunocompetent skeletal muscle in the context of aging
and muscular dystrophy.
Here, we report an engineered, synthetic hydrogel-basedmatrix that
promotes primary MuSC survival, proliferation, and differentiation in
3D. MuSCs exhibited robust survival, proliferation, and differentiation
in synthetic hydrogels functionalizedwith the integrin-targetingArg-Gly-
Asp (RGD) adhesive peptide and cross-linked with protease-degradable
peptides. Proliferation of MuSCs was further enhanced through opti-
mization of the hydrogel’s mechanical properties and mesh size.
Transplantation of MuSCs using this engineered synthetic matrix to
the supramuscular locus of cryo-injured tibialis anterior (TA)muscles
of dystrophic (mdx-4CV) and aged (23months old) mice significantly
improved donor cell engraftment compared to cell-free and collagen
gel controls. Collectively, the results establish this engineered synthetic
matrix as a versatile platform for stem cell therapy in the context of
skeletal muscle injury, aging, and neuromuscular diseases. o
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/RESULTS
Modular hydrogel platform as a synthetic MuSC matrix
To engineer a biofunctional matrix for MuSC culture and delivery,
we selected a synthetic hydrogel platform based on a four-arm
poly(ethylene glycol) (PEG) macromer, with its ends functionalized
with maleimide groups (PEG-4MAL) as the base material. The PEG-
4MAL platform exhibits excellent biocompatibility in vivo and cyto-
compatibility with various cell types, including pancreatic islets and
skeletal myoblasts (47–50). Furthermore, PEG-4MAL hydrogels have
significant advantages over naturally derived extracellular matrices
and other synthetic gels, such as the ability to independently tune
mechanical, structural, and biochemical properties and minimization
of lot-to-lot variability (50, 51). In this synthetic platform, themaleimide
groups in PEG-4MAL macromers are efficiently reacted with thiol-
containing cell-adhesive peptides through Michael-type addition,
enabling stoichiometric functionalization of the macromer. The re-
maining maleimide groups are then reacted with cysteine-flanked pep-
tides (for example,GCRDVPMSMRGGDRCG) to cross-linkmacromers
to yield a hydrogelwith a highly defined structural network (Fig. 1A). The
cytocompatible maleimide-thiol reaction can be performed in the pres-
ence of cells to yield cell-laden 3Dconstructs. Thus,we sought to engineer
a biofunctional matrix capable of promoting MuSC survival, prolifera-
tion, and differentiation using the PEG-4MALhydrogel platformby eval-Han et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018uating the effects of adhesive ligand type, mechanical and diffusive
transport properties, and protease degradability (Fig. 1A).
RGD-presenting synthetic matrix supports myogenesis
An important consideration for engineering a synthetic matrix for
adherent cells is the presentation of context-dependent, cell-adhesive
ligands, as cell adhesion is a necessary process for survival, proliferation,
migration, and differentiation (52–54). To identify optimal cell-adhesive
ligands forMuSC function, we evaluated the effects of cell-binding syn-
thetic peptides found in fibronectin and laminin, prominent extracellular
matrix proteins constituting the native MuSC niche (table S1). We
isolated Pax7+ primary MuSCs by flow cytometry using a previously
established set of markers (CD45−, CD11b−, Ter119−, Sca1−, CXCR4+,
and b1 integrin+; Fig. 1B) (28) and encapsulated the cells as nonaggre-
gated single cells in 4% (w/v) PEG-4MALhydrogels (20-kDamacromer)
containing either 1.0 mM RGD, RDG (scrambled control), YIGSR, or
C16 synthetic peptides and cross-linked with protease-degradable pep-
tides (fig. S1). All these hydrogel formulations exhibit equivalent
mechanical, diffusive transport, and protease-degradable properties
(51). After 6 days of culture in growthmedia containing basic fibroblast
growth factor (FGF-2), MuSCs cultured in RGD-presenting hydrogels
proliferated and formed noncircular MyoD+ myogenic colonies, com-
pared to RDG-presenting (P < 0.0001), YIGSR-presenting (P < 0.05),
and C16-presenting (P < 0.001) hydrogels (Fig. 1, C and D). For
RGD-presenting hydrogels, cell packing density within amyogenic col-
ony was significantly lower compared to the other hydrogel formula-
tions (P < 0.0001), suggesting cellular migration (Fig. 1, C and E).
Furthermore, myogenic colonies formed in RGD-presenting hydrogels
were significantly larger compared to colonies formed in RDG-, YIGSR-,
and C16-presenting hydrogels (P < 0.0001; Fig. 1, C and F). However,
when cell proliferationwas assessed via EdU (5-ethynyl-2′-deoxyuridine)
incorporation, we observed no statistical differences among hydrogels
containing different cell-adhesive peptides on both days 3 and 6 of
culture (Fig. 1, C and G, and fig. S2A). Furthermore, MuSCs in RGD-,
RDG-, C16-, and YIGSR-presenting hydrogels exhibited similar levels of
MuSC activation (>60% Pax7+ and >95% MyoD+ activated MuSCs per
colony; fig. S2, B andC) after 72 hours of culture, indicating that potential
differences in activation state did not contribute to the differential myo-
genic colony formation. Notably, MuSCs cultured in RGD-presenting
hydrogels exhibited significantly less TUNEL+ cells compared toMuSCs
in scrambledRDG-presenting hydrogels at day 1 after encapsulation (P<
0.05), indicating that hydrogels presenting theRGDcell-adhesive peptide
promote cell survival and subsequently support the formation of robust
myogenic colonies compared to hydrogels presenting scrambled RDG
control peptide (Fig. 1, H and I).
Cellular fusion is a major hallmark of differentiated myocytes. To
determine whether RGD-presenting hydrogels supportMuSC differen-
tiation, we mixed GFP+ and TdTomato+ MuSCs in a 1:1 ratio and en-
capsulated them within RGD- or RDG-presenting hydrogels. We
reasoned that fused GFP+ and TdTomato+ cells would exhibit both flu-
orescent proteins in the cytosol, indicative of differentiation and fusion
(fig. S3A). To prime differentiation, we initially cultured MuSCs in ei-
ther RGD- or RDG-presenting hydrogels in growth media with daily
supplementation of FGF-2 for 6 days and then in differentiation media
for an additional 4 days. Cells cultured in RDG-presenting hydrogels
did not fuse, and cells remained inmulticellular clusters homogeneously,
composed of eitherGFP+ or TdTomato+myoblasts (Fig. 1J and fig. S3B).
In contrast, cells cultured inRGD-presentinghydrogelsweremorpholog-
ically distinct, where the cells were elongated and spread (Fig. 1J and2 of 14
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 fig. S3B). Moreover, cell fusion events were present, indicated by mul-
tinucleated myotubes expressing both GFP+ and TdTomato+ in the
cytosol, with a significantly higher fusion index compared to control RDG-
presenting hydrogels (P < 0.0001; Fig. 1J and fig. S3, B and C). Dif-
ferentiated myotubes exhibited spontaneous contraction in the
RGD-presenting hydrogels, indicating functional differentiation of
MuSC (movie S1). Despite the marked differences in cellular fusion
andmorphology, cells in both RGD- and RDG-presenting hydrogels
stained positive for desmin andmyosin heavy chain upon culturing
in differentiation media (fig. S3D) and exhibited similar levels of
myogenin and desmin gene expression (fig. S3E). This result suggests
that the reduced serum content of the differentiationmedia primes theHan et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018cells to differentiate, but cells are unable to undergo fusion in the non-
adhesive RDG-presenting hydrogels, corroborating the importance of
cell-adhesive ligands in the cellular fusion process. b3 integrin, amajor
target of RGD tripeptide sequence, has been shown to be an essential
factor for myotube formation (54). Collectively, these results indicate
that presentation of RGD adhesive peptide in PEG-4MAL hydrogels
promotes MuSC in vitro survival, proliferation, and differentiation.
PEG-4MAL macromer density modulates MuSC proliferation
The biophysical properties of the extracellular matrix have a profound
impact on cellular functions (55). In the PEG-4MAL hydrogel system,
altering the PEG-4MAL polymer density can modulate the mechanicalA
C
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Fig. 1. RGD-presenting PEG-4MAL hydrogels promote MuSC survival, proliferation, and differentiation. (A) Schematic of cell-laden hydrogel. Synthetic hydrogel
platform can be biofunctionalized with cell-adhesive ligands and protease-degradable cross-linkers. (B) Representative fluorescence-activated cell sorting plot of
MuSCs. SSC, side scatter; PI, propidium iodide; ITGB1, b1 integrin. (C) Representative z-projections of myogenic colonies formed in PEG-4MAL hydrogels presenting
synthetic cell adhesive peptides (day 6). Scale bars, 100 mm. (D) Quantification of myogenic colony circularity. n = 9 and 10 colonies. *P < 0.05, ***P < 0.001, and ****P <
0.0001 versus RGD via Kruskal-Wallis with Dunn’s test. (E) Quantification of myogenic colony cell packing density. n = 9 and 10 colonies. ****P < 0.0001 versus all groups
via one-way analysis of variance (ANOVA) with Tukey’s test. (F) Quantification of myogenic colony size. n = 9 and 10 colonies. ****P < 0.0001 versus all groups via one-
way ANOVA with Tukey’s test. (G) Quantification of myogenic colony proliferation. n = 9 and 10 colonies. *P < 0.05 via two-way ANOVA with Sidak’s test. (H) Repre-
sentative z-projections of DNA and terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining (day 1). Scale bars, 50 mm.
(I) Quantification of TUNEL+ cells. n = 5 hydrogels. #P < 0.05 via unpaired two-tailed t test. (J) Representative z-projections of green fluorescent protein–positive (GFP+) and
TdTomato+ MuSCs. Cells were cultured in growth media for 6 days and then in differentiation media for 4 days. GFP/TdTomato-fused cells appear yellow. Scale bars, 100 mm.3 of 14
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6%, w/v), we introduce more cross-links to the system, resulting in the
formation of a tighter polymer network and increased hydrogel storage
modulus (from 150 to 300 Pa; Fig. 2, A and B). As tighter polymer
networks are formed with increasing polymer density, the mesh size
decreases (Fig. 2, A and C). To evaluate the effects of polymer density
on MuSC function, we encapsulated and cultured freshly isolated
MuSCs within 3 to 6% 20-kDa PEG-4MAL hydrogels containing
1.0mMRGDand cross-linkedwith protease-degradable peptides.MuSCs
cultured in 3 and 4% PEG-4MAL hydrogels formed significantly larger
myogenic colonies compared to cells in 6% PEG-4MAL hydrogels at
day 4 (P < 0.01 and P < 0.001, respectively; Fig. 2, D and E). Furthermore,Han et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018the number of colonies formed in 3% PEG-4MAL hydrogels was signifi-
cantly greater compared to that in 5 and 6% PEG-4MAL hydrogels (P <
0.05; Fig. 2, D and F). Finally, 3 and 4% PEG-4MAL hydrogels promoted
significantly increased cell proliferation compared to 6% PEG-4MAL hy-
drogels (P < 0.05 and P < 0.01, respectively; Fig. 2, G and H), collectively
indicating that 3 to 4%PEG-4MALhydrogels support optimalMuSCpro-
liferation and myogenic colony formation.
To determine the effects PEG-4MAL polymer density on MuSC
activation, we examined Pax7+/MyoD+ expression of MuSCs in 4 and
6% PEG-4MAL hydrogels presenting 1.0 mM RGD and cross-linked
with protease-degradable peptides at 76 hours after encapsulation. Al-
though no differences in MyoD expression were observed, myogenic o
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Fig. 2. PEG-4MAL macromer density modulates MuSC proliferation. (A) Schematic describing the changes in hydrogel mesh size and mechanical properties as a
function of PEG-4MAL macromer density. (B) Storage modulus of hydrogels for different macromer densities. n = 3 hydrogels. *P < 0.05 (solid line) and **P < 0.01
(dashed line) via one-way ANOVA with Tukey’s test. (C) Estimation of hydrogel mesh size based on the measured storage modulus. n = 3 hydrogels. *P < 0.05 (solid line)
and **P < 0.01 (dashed line) via one-way ANOVA with Tukey’s test. (D) Representative z-projections of myogenic colonies formed in PEG-4MAL hydrogels as a function
of macromer density (day 4). Scale bars, 100 mm (top row) and 250 mm (bottom row). Percentage values indicate PEG-4MAL macromer density. (E and F) Quantification
of myogenic colony (n = 18 colonies) and density (n = 3 and 4 hydrogels). *P < 0.05, **P < 0.01, and ***P < 0.001 via one-way ANOVA with Tukey’s test. (G) Repre-
sentative z-stack projections of EdU-labeled myogenic colonies (day 4). Scale bars, 100 mm. (H) Quantification of EdU+ nuclei. n = 12 to 15 colonies. *P < 0.05 and **P <
0.01 via one-way ANOVA with Tukey’s test. (I) Representative z-projections of MuSCs cultured in 4% 20-kDa and 2.5% 10-kDa PEG-4MAL hydrogels (day 4). Scale bars,
100 mm. (J) Quantification of myogenic colonies. n = 10 colonies. Bar graphs are presented as mean ± SD.4 of 14
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 colonies formed in 6%PEG-4MALhydrogels exhibited significantly de-
creased levels of Pax7 expression compared to those formed in 4%PEG-
4MAL hydrogels (fig. S4, A and B).
To assess whether the increased cell proliferation with decreasing
macromer density is an effect of mesh size or mechanical properties,
we encapsulated and cultured MuSCs in 2.5% 10-kDa PEG-4MAL
and 4% 20-kDa PEG-4MAL hydrogels, both presenting 1.0 mM
RGD and cross-linked with protease-degradable peptides. The 2.5%
10-kDa PEG-4MAL hydrogels have decreased solute diffusivity com-
pared to 4% 20-kDa PEG-4MAL hydrogels (P < 0.05) due to the re-
duced molecular weight of the macromer while exhibiting comparable
mechanical properties (P> 0.05) due to similar average cross-link density
(fig. S5, A to F). MuSCs cultured in 2.5% 10-kDa PEG-4MAL did not
form myogenic colonies on day 4, whereas colonies readily formed in
4% 20-kDa PEG-4MAL hydrogels (Fig. 2, I and J), suggesting that mesh
size imparts a significant impact on the proliferation capacity of MuSCs
in a 3D-culture setting.
Matrix degradability is required for MuSC function
Extracellular matrix degradability is an important factor for dynamic
remodeling of the cellular microenvironment (56). We hypothesized
that the degradability of the synthetic PEG-4MAL hydrogel is a critical
feature for MuSC function, including survival and proliferation. To test
this hypothesis, we encapsulated freshly isolated TdTomato+MuSCs in
RGD-functionalized 4% 20-kDa hydrogels cross-linked using either a
protease-degradable peptide (GCRDVPMSMRGGDRCG; protease-
sensitive) or protease-insensitive hexa(ethylene glycol) dithiol (protease-
insensitive). MuSCs cultured in protease-degradable hydrogels formed
robust myogenic colonies after 4 days in culture, whereas we observed
minimally viable MuSCs and no myogenic colonies in the protease-
insensitive hydrogels (Fig. 3, A and B). A singleMuSC encapsulated in
protease-sensitive matrix readily degraded the surrounding matrix to
proliferate and form a robust myogenic colony over time, whereas a
MuSC in nondegradable, protease-insensitive matrix remained entrapped
and unable to proliferate over time (Fig. 3C). Furthermore, themechanical
properties of protease-sensitive hydrogels containingMuSC declined with
time in culture (Fig. 3D), and the calculated mesh size (Fig. 3E) increased
over culture time. As expected, themechanical properties andmesh size of
MuSC-laden protease-insensitive cells remained relatively constant over
time in culture. These results indicate that use of protease-degradable
cross-linking peptides, which enable on-demand degradation of the
cellularmicroenvironment, is essential forMuSC survival andproliferation
in vitro within these synthetic niches.
Synthetic matrix supports higher MuSC proliferation
potential than natural matrices
Collagen gels are commonly used as a natural extracellular matrix for
cell culture in 3D. To determine how the engineered PEG-4MAL hy-
drogels perform in supporting MuSC function in comparison to colla-
gen gels as a benchmarkmaterial, we encapsulated freshly isolatedGFP+
MuSCs in either RGD-functionalized 4% 20-kDa hydrogels cross-
linked using protease-degradable peptides or type I collagen gels
(2.7 mgml−1; storagemodulus, 70 ± 16 Pa).Myogenic colonies formed
after 4 days of culture were significantly larger in the PEG-4MAL syn-
thetic hydrogels compared to collagen gels (P < 0.0001; Fig. 4, A and B).
Despite the significant size differences in myogenic colonies formed in
the PEG-4MALhydrogels and collagen gels, we observed no differences
in cell proliferation on day 4 of culture (P > 0.05; Fig. 4, C andD). How-
ever, assessment of dead cells at 1 day after encapsulation revealed thatHan et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018cell viability is significantly lower in collagen gels compared to the PEG-
4MALhydrogels (P < 0.0001; Fig. 4, E and F, and fig. S6A).We attribute
the larger myogenic colonies formed in the PEG-4MAL hydrogels to
higher cell viability upon encapsulation. To eliminate potential effects
of material stiffness on myogenic colony formation in 3D, we cultured
MuSCs in either type I collagen gel (2.7mgml−1) or RGD-functionalized
2.8%20-kDaPEG-4MALhydrogels cross-linkedwith protease-degradable
peptides, which exhibit similar storage modulus as type I collagen gel
(2.7 mg ml−1; fig. S6B). Despite comparable mechanical properties, my-
ogenic colonies formed in 2.8% PEG-4MAL hydrogels were significantlyA
C
D E
B
Fig. 3. Protease degradability of the hydrogel is essential for MuSC prolifer-
ation. (A) Representative z-projections of MuSCs cultured in RGD-functionalized
hydrogels synthesized with protease-sensitive and protease-insensitive cross-linkers
(day 4). Scale bars, 100 mm. TdTom., TdTomato. (B) Quantification of myogenic colo-
nies. Median ± interquartile range. n = 20. (C) Representative myogenic colony for-
mation over time in protease-sensitive hydrogel and in protease-insensitive
hydrogels over 5 days. Scale bars, 50 mm (main images) and 10 mm (insets). (D) Stor-
age modulus and (E) mesh size of protease-sensitive and protease-insensitive hydro-
gels over 5 days. **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus time-matched
protease-sensitive hydrogels via two-way ANOVA with Sidak’s test. n = 4 hydrogels
per time point. Mean ± SD.5 of 14
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 greater than colonies formed in collagen gel (2.7 mg ml−1; fig. S6, C and
D). This result suggests that other biophysical and biochemical differ-
ences, such as cell binding site (type anddensity),materialmicrostructure
and function, and transport properties, regulate the differences inMuSC
function between these biomaterial systems.
In the context of skeletal muscle, Matrigel may be a more appropri-
ate naturally derived matrix for myogenic cell culture, as a major con-
stituent ofMatrigel is laminin. To assessMuSC function in comparison
toMatrigel as an additional benchmarkmaterial, we encapsulated fresh-
ly isolated GFP+ MuSCs in either RGD-functionalized 4% 20-kDa hy-
drogels cross-linked with protease-degradable peptides or Matrigel
(storage modulus, 25.2 ± 7.8 Pa). After 4 days of culture, we observed
significantly larger myogenic colonies in the PEG-4MAL synthetic hy-
drogel compared toMatrigel (P<0.0001; Fig. 4,G andH). Furthermore,
myogenic colonies formed in Matrigel were morphologically rounder
and closely clustered (Fig. 4G). Although Matrigel is an appropriate
reference material, it is important to highlight limitations associated
withMatrigel. Matrigel is generated from the Engelbreth-Holm-Swarm
sarcoma that is rich in undefined extracellular matrix proteins. As a re-
sult, Matrigel is subjected to significant lot-to-lot variability in terms of
composition and mechanical properties and poses potential risk of
pathogen transfer and immunogenicity, significantly limiting its clinical
translation. Nonetheless, the results collectively demonstrate that the
engineered synthetic matrix supports higher MuSC proliferation
potential than collagen gels and Matrigel.
Synthetic matrix boosts engraftment in dystrophic
muscle trauma
Acute muscle trauma imparts significant burden on the endogenous
MuSC population to regenerate the damaged muscle (25–27), and the
regenerative potential of muscle is further challenged when the normalHan et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018mechanisms of muscle regeneration and homeostasis are chronically
dysregulated (1). For instance, DMDmuscles lacking dystrophin exhib-
it reduced mechanical integrity and are prone to sarcolemma rupture
upon repeated contraction. Moreover, dystrophin-deficient MuSCs ex-
hibit abnormal mitosis and asymmetric division capacity (14, 15), ex-
acerbating the detrimental consequences ofmuscle injury. Transplantation
of MuSCs stimulates muscle regeneration through cellular engraftment
(28); however, cell delivery via direct injection poses several challenges
at the translational level, including poor cell survival and limited appli-
cability to traumatic injuries. To this end, we applied the bioengineered
synthetic matrix to deliver MuSCs to the superficially injured TA
muscles ofmdx-4CVmice, which exhibit chronic muscle degeneration
and regeneration. We hypothesized that MuSCs delivered within the
engineered PEG-4MAL hydrogel, which supports survival, activation,
and proliferation, would migrate into the host muscle, resulting in
enhanced cellular engraftment. The PEG-4MAL hydrogel system
enables in situ polymerization and direct integration to host tissue
through thiol-presenting tissue andmaleimide functional groups to im-
prove in vivo cell retention and delivery, thus providing a major advan-
tage over other synthetic and natural materials (50). TA muscles of
recipientmdx-4CVmice (13 to 19 weeks old) were injured by exposing
the muscle surface to a liquid nitrogen–cooled probe before transplan-
tation (Fig. 5A). A cryo-injury model was selected because it induces
more localized injury compared to other commonly used models, such
as cardiotoxin and notexin injections, through ablation of myofibers
and mononuclear cells at the site of injury and necessitates MuSCs to
migrate in from the noninjured sites (57, 58). To evaluate the effects of
PEG-4MAL polymer density on MuSC engraftment in vivo, we
delivered freshly isolated b-actin GFP+/luciferase+MuSCs encapsulated
in 3% 20-kDa PEG-4MAL hydrogels containing 1.0 mM RGD, 6%
20-kDa PEG-4MAL hydrogels containing 1.0 mMRGD, or suspendedA
E F G H
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Fig. 4. Synthetic matrix supports higher MuSC proliferation potential than natural matrices. (A) Representative z-projections of myogenic colonies formed in 4%
PEG-4MAL and collagen gels (2.7 mg ml−1; day 4). Scale bars, 100 mm. (B) Quantification of myogenic colony size. n = 14 to 19 colonies. ****P < 0.0001 via two-tailed
Mann-Whitney U test. (C) Representative z-projections of EdU-labeled myogenic colonies formed in 4% PEG-4MAL and collagen gels (2.7 mg ml−1; day 4). Scale bars,
100 mm. (D) Quantification of EdU+ nuclei. n = 19 colonies. P = 0.11 via unpaired two-tailed t test. (E) Representative z-projections of GFP+ MuSCs 1 day after en-
capsulation in 4% PEG-4MAL and collagen gels (2.7 mg ml−1). BF, bright field. Scale bars, 100 mm. (F) Quantification of TOTO-3+ dead MuSCs 1 day after encapsulation. n = 7
hydrogels. ****P < 0.0001 via unpaired two-tailed t test. (G) Representative images of GFP+ MuSCs 4 days after encapsulation in 4% PEG-4MAL and Matrigel. Scale bars,
100 mm. (H) Quantification of GFP+ myogenic colony area 4 days after encapsulation. n = 16 to 19 colonies. ****P < 0.0001 via two-tailed Mann-Whitney U test.6 of 14
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Fig. 5. Synthetic matrix enhances engraftment in dystrophic muscle trauma. (A) Schematic of injury and cell delivery. We applied cryo-injury on the surface of TA
muscle. We supramuscularly delivered freshly isolated MuSCs in media (hydrogel-free) or encapsulated in hydrogel. Gastroc., gastrocnemius muscles. (B) Representative
IVIS images of mdx-4CV mouse hindlimbs treated with cell-laden 3% 20-kDa PEG-4MAL, 6% 20-kDa PEG-4MAL, or media (12,500 MuSCs per TA). (C) Quantification of
bioluminescence over time. Mean ± SEM. n = 8 per condition. *P < 0.05, **P < 0.01, and ****P < 0.0001 versus hydrogel-free via Tukey’s test within time. ++P < 0.01
versus 6% PEG-4MAL via Tukey’s test within time. ⋆P < 0.05 for interactions, xxP < 0.01 for biomaterials effect, and ###P < 0.001 for time effect via two-way repeated-
measures ANOVA. (D) Quantification of area under the bioluminescence curve (AUC). Mean ± SEM. n = 8 per condition. *P < 0.05 versus hydrogel-free via one-way
ANOVA with Tukey’s test. (E) Representative cross sections of TA muscles treated with cell-laden 3% 20-kDa PEG-4MAL, 6% 20-kDa PEG-4MAL, or media on day 28 after
transplantation. Scale bars, 50 mm. (F) Quantification of GFP+ fibers per square millimiter. n = 8 per condition. *P < 0.05 versus all groups via Kruskal-Wallis with Dunn’s
test. (G) Representative cross sections of TA muscles treated with cell-laden 3% 20-kDa PEG-4MAL functionalized with RGD or RDG peptides at day 28 after transplantation
(12,500 MuSCs per TA). Scale bars, 50 mm. (H) Quantification of GFP+ fibers per square millimeter. n = 6 per condition. *P < 0.05 via two-tailed Mann-Whitney U test.
(I) Representative IVIS images of MuSC-transplanted mdx-4CV mice. TA muscles were cryo-injured, and 20,000 MuSCs were delivered to the injured TA muscles in
either PEG-4MAL hydrogel (left) or collagen gel (2.7 mg ml−1; right). (J) Quantification of bioluminescence over time. Mean ± SEM. n = 5 per condition. ++P < 0.01
within time via Sidak’s test. *P < 0.05 for interactions and biomaterials effect via two-way repeated-measures ANOVA. ###P < 0.05 for time effect via two-way
repeated-measures ANOVA. (K) Quantification of AUC. n = 8 per condition. *P < 0.05 via two-tailed paired t test. (L) Representative cross sections of TA muscles
treated with 50,000 MuSCs in either PEG-4MAL or collagen gel (2.7 mg ml−1). Scale bars, 100 mm. (M) Quantification of engrafted GFP+ fibers per square millimeter. n
= 8 per condition. **P < 0.01 via two-tailed Wilcoxon matched-pairs signed-rank test.Han et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018 7 of 14
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 inmedia (hydrogel-free) atop the injured TAmuscles immediately after
muscle injury (Fig. 5A). Both PEG-4MAL gels were cross-linked using
protease-degradable peptides. We elevated and sustained the bio-
luminescence signal of MuSCs delivered in 3% PEG-4MAL hydrogels
through day 28 after transplantation compared to hydrogel-free condi-
tion (P<0.01 over time andP<0.05 onday 28; Fig. 5, B andC).Analysis
of the area under the bioluminescence curve further substantiated this
observation (P < 0.05; Fig. 5D). MuSCs delivered in 3% PEG-4MAL
hydrogels successfully differentiated and formed GFP+ fibers, whereas
MuSCs delivered in 6% PEG-4MAL hydrogels or media alone did not
engraft (P < 0.05; Fig. 5, E and F). Collectively, the results indicate that
MuSCs delivered in 3%PEG-4MALhydrogels directly on top of acutely
injured dystrophic TA muscles support in vivo retention, survival, and
proliferation and promote cellular engraftment into the injured host
muscle.
We next examined the importance of the RGD adhesive peptide in
the delivery hydrogel vehicle on MuSC engraftment. We compared
GFP+ MuSC transplantation efficacy using 3% PEG-4MAL hydrogels
cross-linked with protease-sensitive peptides and functionalized with
either 1.0 mM RGD or 1.0 mM scrambled RDG in the cryo-injured
TAmuscles ofmdx-4CVmice.We observed a significantly higher num-
ber of GFP+ fibers in the RGD-presenting hydrogel group compared to
the scrambled RDG-presenting hydrogel group on day 28 after trans-
plantation (P < 0.05; Fig. 5, G and H), demonstrating that presentation
of RGDcell-adhesive peptidewith the delivery vehicle is required for the
engraftment of delivered MuSCs.
To directly compare MuSC transplantation efficacy of the engi-
neered PEG-4MAL hydrogels to collagen gels, we monitored the bio-
luminescence signal of MuSCs delivered to injured muscle using either
RGD-presenting 3% PEG-4MAL hydrogels cross-linked with protease-
sensitive peptides or collagen gels (2.7 mg ml−1) over time. MuSCs
delivered using the PEG-4MALhydrogels exhibited a significantly higher
overall bioluminescence signal compared to collagen over the course of
28 days (P < 0.05; Fig. 5, I and J). Further analysis of the area under
the bioluminescence curve substantiated thatMuSCs delivered using
PEG-4MAL hydrogels resulted in significantly higher engraftment
thanMuSCs delivered using collagen gels (P < 0.05; Fig. 5K), indicating
superior performance of the PEG-4MAL hydrogel compared to collagen
gels for delivery of MuSCs to injured TA muscles.
The engraftment potential is strongly dependent on the number
of MuSCs delivered (19, 29, 55). To demonstrate the feasibility of
achieving a higher number of engrafted fibers using the engineered PEG-
4MAL hydrogels, we delivered approximately 50,000 freshly isolated
GFP+MuSCs to the cryo-injured TAmuscles ofmdx-4CVmice. Deliv-
ery of MuSCs in 3% PEG-4MAL hydrogels resulted in robust engraft-
ment 28 days after transplantation, where the mean number of GFP+
fibers increased significantly (~15 to 50 fibers/mm2) by increasing the
donor cell quantity (Fig. 5, L andM). Delivery ofMuSCs using collagen
gel resulted in minimal engraftment (Fig. 5, L and M), further demon-
strating the efficacy of the engineered PEG-4MAL hydrogels.
Synthetic matrix boosts MuSC engraftment in aged
muscle trauma
Aged skeletal muscles exhibit impaired regenerative capacity upon
injury (2). To confirm that aged muscles exhibit diminished regen-
eration upon superficial cryo-injury compared to young muscles, we
subjected young (4 months old) and aged (22 months old) muscles to
cryo-injury, as described above, and assessed their native endogenous
regeneration. Young (4 months old) TA muscle regenerated to tissueHan et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018comparable to native uninjured TA muscle by day 14 after injury,
whereas aged (22months old) TAmuscle did not completely regenerate
by day 14 after injury, as indicated both by the smaller fiber cross-
sectional area and by the higher presence of centrally localizedmyonuclei
(P < 0.0001; Fig. 6, A and B). To test whether the engineered PEG-4MAL
hydrogel can alsopromoteMuSCengraftment in injured agedmuscle,we
delivered freshly isolated b-actin GFP+/luciferase+ MuSCs encapsulated
in 3%20-kDaPEG-4MALhydrogels containing 1.0mMRGDand cross-
linked with protease-degradable peptides or suspended in media
(hydrogel-free) to the supramuscular locus of the cryo-injured TA
muscles of aged mice (23 months old). Delivery of MuSCs using the
PEG-4MAL hydrogel resulted in a progressive increase in the bio-
luminescence signal up to 7 days after transplantation, and this signal
was sustained through day 28 after transplantation (Fig. 6, C and D). In
contrast, MuSCs delivered without the hydrogel resulted in no change
in the bioluminescence signal over time, and this signal was significantly
lower than the signal for the hydrogel group (P < 0.05; Fig. 6, C to E).
Consistent with these results, we observed increased numbers of GFP+
fibers, indicative of transplanted cell engraftment, for muscles treated
with MuSCs delivered within PEG-4MAL gels, whereas we observed
no GFP+ fibers for muscles treated with MuSCs without the hydrogel
carrier (Fig. 6F). These results show that PEG-4MAL hydrogel pro-
motes donor MuSC retention, survival, proliferation, and engraftment
in injured aged muscle.DISCUSSION
Here, we engineered a synthetic hydrogel that promotesMuSC survival,
proliferation, and differentiation in 3D culture. Furthermore, we
demonstrated that the engineered PEG-4MAL hydrogel can be used as
a delivery vehicle to transplant MuSCs to injured skeletal muscles that
exhibit dysregulated homeostasis and regeneration, such as in aging and
muscular dystrophy. This biomaterial platform offers a unique advan-
tage for delivering cells to traumatically injured muscles with disrupted
structural tissue integrity, as the maleimide functional groups of the
PEG-4MAL system react with thiol-containing molecules and tissues
to form covalent bonds via Michael-type addition under physiologic
conditions, and offers the ability to firmly integrate the cell-encapsulated
hydrogel to biological tissues (50). The engineered hydrogel is based
solely on synthetic materials, which offers major advantages over natu-
rally derived hydrogels including collagen and Matrigel. Synthetic
matrices areminimally susceptible to lot-to-lot variations and pathogen
transfer and thus are more suitable for translating the technology to the
clinics. Moreover, the biophysical and biochemical properties of the
synthetic matrix can be modulated in a highly precise and controlled
manner, enabling identification of key cellular niche parameters for
directing cell function.
To design a synthetic matrix that enhances MuSC function (that is,
survival, activation, proliferation, and differentiation) for cell delivery
applications, we reasoned that key factors found in the native MuSC
niche must be incorporated into an otherwise biologically inert PEG-
based hydrogel. MuSCs reside in between muscle fiber sarcolemma
and its surrounding laminin-rich basal laminamatrix. Upon injury, fib-
ronectin content in the basal lamina transiently increases and induces
MuSC expansion (59). In addition, fibronectin has been identified as a
preferred adhesion substrate for MuSCs, where fibronectin targets
b1 integrin and synergistically acts with FGF-2 to activate common
downstream signaling through the mitogen-activated protein kinase
ERK (extracellular signal–regulated kinase) and protein kinase B for8 of 14
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 MuSC expansion and self-renewal (52, 60). Here, we showed that the
RGD peptide, positioned within the cell-binding region of fibronectin,
laminin, vitronectin, and collagen types I and IV (61), is necessary to
promote primaryMuSC survival, expansion, and differentiation within
the synthetic hydrogel. Whereas the RGD peptide has been shown to
promote C2C12 and primarymyoblast adhesion, proliferation, and dif-
ferentiation (49, 62), the effect of the RGD peptide as a bioactive cell-
adhesive ligand for quiescent and activatedMuSC function has not been
established previously. RGD binds b1 integrin and b3 integrin (61),
which are critical for MuSC expansion and differentiation (54, 60), re-
spectively. Binding of RGD to MuSC integrins also likely promotes cell
survival through inhibition of anoikis (Fig. 1, H and I). With determi-
nation of the appropriate biophysical parameters and incorporation of
on-demand matrix degradation capability, we achieved high levels of
survival and proliferation ofMuSCs (Figs. 2 and 3 and fig. S5). Although
it is outside the scope of the current study, there is potential to further
engineer this platform to promote quiescence and self-renewal in combi-
nation with a quiescence medium (34) and presentation of asymmetrical
and/or spatiotemporal cues for ex vivo expansion of MuSCs.Han et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018We also established a biomaterial-mediated cell delivery strategy for
treating skeletal muscle trauma involving severe lacerations, burns, and
surgical resections, where intramuscular injections may not be directly
applicable. Although healthy skeletal muscles have remarkable regen-
erative potential, their regenerative capacity becomes severely limiting
with trauma, and the problem is further exacerbated in conditions with
impaired muscle regeneration, such as aging and muscular dystrophy.
To demonstrate the feasibility of supramuscular delivery of MuSCs in
these potential clinical situations, we used cryo-injured dystrophic and
agedmuscles as in vivo proof-of-concept systems in this study. Delivery
of freshly isolatedMuSCs using the engineered PEG-4MAL hydrogel to
the supramuscular locus of the injured muscle promoted in vivo cell
survival, retention, proliferation, and engraftment in both aging and
muscular dystrophy contexts compared to collagen gels and hydrogel-
free controls, demonstrating the versatility of this platform to treat dif-
ferent muscle conditions. Note that here, we delivered 12,500 to 20,000
freshly isolated MuSCs per nonirradiated, immunocompetent TA
muscle (Figs. 5, B to K, and 6). The engraftment rate and degree of en-
graftment are strongly dependent on the number of MuSCs deliveredA
C
F
D E
B
Fig. 6. Synthetic matrix enhances engraftment in aged muscle trauma. (A) Hematoxylin and eosin images of young (4 months) and aged (22 months) TA muscles.
Muscles were cryo-injured, and endogenous regeneration was assessed on day 14 (D14). (B) Quantification of cross-sectional area (CSA). Box-and-whiskers plot with 10
to 90 percentile whiskers. We measured ≥138 fibers. p.i., postinjury. ****P < 0.0001 versus young uninjured and young D14 postinjury; ####P < 0.0001 versus aged
uninjured via one-way ANOVA with Dunn’s test. (C) Representative IVIS images of aged mice (23 months). TA muscles were cryo-injured, and 20,000 MuSCs
encapsulated in PEG-4MAL hydrogel (left) or suspended in media (right) were transplanted. (D) Quantification of bioluminescence over time. Mean ± SEM. n = 6
per condition. *P < 0.05 via two-tailed Wilcoxon matched-pairs signed-rank test within time. (E) Quantification of AUC. n = 6 per condition. *P < 0.05 via two-tailed
Wilcoxon matched-pairs signed-rank test. (F) Cross sections of TA muscles at day 28 after transplantation. Scale bars, 50 mm.9 of 14
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 (19, 29, 55), and thus, this biomaterial-mediated cell delivery strategy
could be further potentiated by increasing the donor cell quantity. We
demonstrate that increasing the donor cell number significantly en-
hances cell engraftment (Fig. 5, L and M). For translation of cell-based
technologies to the clinic, challenges associated with sourcing and
manufacturing MuSCs need to be overcome through development of
ex vivo expansion technologies and generation of induced pluripotent
stem cell–derivedmyogenic progenitor cells (34, 55, 63). Finally, it would
also be important to further extend the current strategy to more severe
injury models, such as volumetric muscle loss where the muscle archi-
tecture and function are irreversibly compromised. Nonetheless, the bio-
material presented here sets a promising foundation to deliver cells and
biologics to augment skeletal muscle regeneration upon trauma.
To overcome inherent limitations and challenges presented by direct
cell delivery, numerous natural and synthetic biomaterials have been
developed for cell transplantation to skeletal muscle (34–45, 64). Al-
though biomaterial-assisted cell delivery critically mitigates direct cell
delivery challenges and improves therapeutic outcomes, many of the
previous investigations focused on delivering cultured myoblasts
(36–38, 40, 42), where their engraftment potency is severely restricted
compared to quiescence MuSCs (33, 34, 39, 55). Quiescent MuSCs lose
potency within 7 days of expansion in vitro and result in poor survival
and engraftment in the host muscle upon transplantation (34, 55), sig-
nificantly limiting the translational potential. To further address these
challenges and improve therapeutic outcomes, natural and natural-
synthetic composite hydrogels have been engineered to facilitate the
delivery of quiescent MuSCs and demonstrated positive effects in
promoting MuSC engraftment (34, 35, 39). More recently, synthetic
scaffolds for MuSC delivery have been developed to circumvent
potential limitations associated with naturally derived materials (64),
such as susceptibility to lot-to-lot variations and pathogen transfer.
However, previous evaluations of biomaterials for quiescent and acti-
vated MuSC delivery used preirradiated and immunocompromised
[for example,NOD/Scid (nonobese diabetic/severe combined immuno-
deficient), RAG2 (recombination activating gene 2)/g-chain knockout,
NSG (NOD/Scid/g), and athymic nude] mice, diminishing the clinical
applicability. For instance, engraftment of donorMuSCs in the presence
of competent hostMuSCs ismore challenging (65). Furthermore, inter-
actions between muscle and immune cells, as well as interactions be-
tween biomaterials and immune cells, critically dictate the regenerative
and therapeutic outcomes of the muscle (66), and thus, contributions
of the host MuSCs and immune system are important considerations
at the translational level. Although it is difficult to directly compare the
current data with previous investigations due to these inherent technical
differences and commercial availability of previously reported materials,
the current study provides important insights into enhancing the delivery
of quiescentMuSCs using a fully syntheticmatrix into nonirradiated, im-
munocompetent dystrophic, and aged skeletal muscles.
In summary, we present an innovative biomaterial-based strategy to
support stem cell therapy for treating skeletal muscle injuries. This plat-
form could be useful for treating acute trauma of craniofacial, extraocu-
lar, and limb muscles and addressing postoperative wounds arising
from surgical tumor ablation and surgical interventions of muscular
dystrophies.With concurrent advancement of effectiveMuSC sourcing,
through ex vivoMuSCmanipulation and induced pluripotent stem cell
technologies, this platform could be further developed for applications
in treatment of large muscle trauma, including laceration, severe burn,
and volumetric muscle loss in combination with spatiotemporal delivery
of proregenerative biologics and emergent gene editing technologies.Han et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018MATERIALS AND METHODS
Animals
C57Bl/6, B6Ros.Cg-DMDmdx-4CV/J, FVB-Tg(CAG-luc,-GFP)
L2G85Chco/J, B6.Cg-Gt(ROSA)26Sortm14(CAG-TdTomato)Hze/J, and B6.
C-Tg(CMV-cre)1Cgn/J mice were obtained from the Jackson Labo-
ratory. C57Bl/6-b-actin-EGFP mice were provided by A. Wagers,
Harvard University. R26R-TdTomato/CMV-cre mice were acquired
by crossing B6.Cg-Gt(ROSA)26Sortm14(CAG-TdTomato)Hze/J and B6.C-
Tg(CMV-cre)1Cgn/J mice. CAG-luc-Ka-b-actin-EGFP mice were
acquired by crossing FVB-Tg(CAG-luc,-GFP)L2G85Chco/J and C57Bl/
6-b-actin-EGFP mice. Both male and female mice were used in this
study in a randomized manner. Mice were housed, aged, and/or bred
in the Physiological Research Laboratory Animal Facility of Georgia
Tech. All animal procedures were conducted under the approval of
the Institutional Animal Care and Use Committee of Georgia Tech.
MuSC isolation
MuSCs were isolated as described previously, withminormodifications
(28). Hindlimb muscles were dissected from 2- to 4-month old mice,
minced, and digested inDulbecco’smodified Eagle’smedium (DMEM)
containing type II collagenase (0.2%; Worthington Biochemical Corp.)
and dispase II (2.5 U ml−1; Roche) for 90 min at 37°C. The digest solu-
tion containing the muscles was triturated every 30 min using a donor
bovine serum (DBS)–coated serological pipette. A two-part volume of
20% DBS in F10 media was added to the digested solution and filtered
through a 70-mm cell strainer. The solution was centrifuged (300g) for
5 min at 4°C to yield cell pellets. Cell pellets were washed using 2%
DBS in Hanks’ balanced salt solution (HBSS; 300g centrifugation for
5 min at 4°C) and resuspended in 2% DBS in HBSS. Cells were incu-
bated with a cocktail of primary antibodies (1:100) consisting of phy-
coerythrin (PE)–conjugated anti-mouse b1 integrin (CD29, 20.0%;
BioLegend), anaphase-promoting complex–conjugated anti-mouse
Sca1 (13.3%, v/v; BioLegend), CD45 (13.3%; BioLegend), CD11b
(13.3%; BioLegend), Ter119 (13.3%; BioLegend), and biotinylated anti-
mouse CD184 (CD184, 26.8%; BDPharmingen) in 2%DBS inHBSS for
30 min on ice. Cells were washed in 2% DBS in HBSS and subsequently
incubated with secondary antibody (Streptavidin PE-Cy7; 1:100;
eBioscience) for 20 min on ice. Stained cells were washed as above, and
propidium iodide−, Sca1−, CD45−, CD11b−, Ter119−, b1 integrin+, and
CXCR4+ cells were sorted via fluorescence-activated cell sorting, as de-
scribed previously (BD FACSAria III Cell Sorter) (28).
Hydrogel synthesis, cell encapsulation, and culture
Four-arm PEG-4MAL macromer (molecular weight, 22,000 or 10,000;
Laysan Bio) was dissolved in 1× phosphate-buffered saline (PBS)
containing 10mMHepes (pH 7.4). Cell adhesive peptides (GRGDSPC,
GRDGSPC, CGGEGYGEGYIGSR, and CGGKAFDITYVRLKF; >95%
purity; GenScript) were dissolved in 1× PBS containing 10 mM Hepes
and added to PEG-4MAL solution to produce functionalized PEG-
4MAL precursors. Freshly isolated MuSCs were then added to the so-
lution containing functionalized PEG-4MAL precursors. To synthesize
cell-encapsulated hydrogels, the solution containing functionalized
PEG-4MAL precursors and cells was mixed with protease-degradable
cross-linking peptide (GCRDVPMSMRGGDRCG; GenScript) or non-
degradable hexa(ethylene glycol) dithiol (Sigma-Aldrich) dissolved in
1× PBS containing 10 mM Hepes and subsequently polymerized at
37°C/5% CO2 for 5 min before adding MuSC growth media (F10 con-
taining1%penicillin/streptomycin, 1%GlutaMAX, and20%horse serum).
Recombinant human FGF-2 (25 ng ml−1; PeproTech) was supplemented10 of 14
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 daily. To prime the MuSCs to differentiate, the growth medium was
replaced with differentiation media (DMEM containing 1% penicillin/
streptomycin, 1% GlutaMAX, and 2% horse serum) on days 5 and
6 of culture. Cells were cultured in the differentiation media for an
additional 4 days.
Cell encapsulation in collagen gel
Freshly isolated MuSCs (10,000 cells per gel) were added to the rat-tail
collagen type Iworking solution consisting of 200mMHepes (10.4%, v/v),
10× DMEM (10.4%), 7.5% NaHCO3 (5.2%), and collagen I (5 mg ml
−1;
54%; Rat Collagen I, lot # 30871G14, Culturex). Before adding cells, pH
of the collagen working solution was adjusted by adding 1 M NaOH.
pH-adjusted, cell-containing collagen solution was polymerized at 37°
C/5% CO2 for 30 min before adding MuSC growth media. Recombi-
nant human FGF-2 (25 ng ml−1) was supplemented daily.
Cell encapsulation in Matrigel
Freshly isolated MuSCs (10,000 cells; 2 of 10 parts) were added to the
Matrigel (8 of 10 parts; phenol and lactose dehydrogenase-elevating
virus–free; lot #5075010,Corning).Cell-containingMatrigelwaspolymerized
at 37°C/5% CO2 for 45 min before adding MuSC growth media. Re-
combinant human FGF-2 (25 ng ml−1) was supplemented daily.
In vitro cell staining and myogenic colony quantification
For EdU labeling, cells encapsulated in hydrogels were incubated in
growth media containing 10 mM EdU for 6 hours. Hydrogels were
fixed in 4% paraformaldehyde for 20 min and subsequently washed
three times in 1× PBS. Cells within the hydrogels were blocked and
permeabilized using blocking buffer [5% bovine serum albumin (BSA),
0.5% goat serum, and 0.5% Triton X-100 in 1× PBS] for 1 hour at room
temperature. EdU detection was performed as per the manufacturer’s
instructions (Invitrogen). TUNEL staining and detection were per-
formed as per the manufacturer’s instructions (Invitrogen). Hydrogels
were incubated with primary antibodies overnight at 4°C, washed three
times in 1× PBS, incubated with secondary antibodies containing
Hoechst (1:1000) overnight at 4°C, and washed again three times in
1× PBS. z-stack projection images were acquired using a confocal micro-
scope (Nikon Eclipse Ti-E C2+).Myogenic colonymorphology, size, and
percent EdU+ nuclei were automatically quantified using ImageJ and
CellProfiler (67). Cell packing density was measured by segmenting the
colonyof interest, converting 4′,6-diamidino-2-phenylindole channel of a
MuSC colony into a binary image (white pixel value, 255; black pixel val-
ue, 0) and subsequently determining the mean pixel value, where the re-
sulting value ranges from 0 (less dense) to 255 (more dense). The mean
pixel values were then normalized by dividing by 255 to obtain a cell
packing density metric that ranges from 0 (less dense) to 1 (more dense).
The fusion index was determined by taking the percentage of nuclei con-
tained in multinucleated myotubes with at least two nuclei.
TOTO-3 iodide dead cell labeling
Freshly isolated b-actin–GFP+ MuSCs were encapsulated in either
PEG-4MAL or collagen gels and cultured in growth media overnight.
TOTO-3 iodide (Invitrogen) was then added to the media at final con-
centration of 1 mM. Cells were incubated at 37°C/5% CO2 for 30 min
z-stack projection images were acquired using a confocal microscope
(Nikon Eclipse Ti-E C2+) equipped with LiveCell system (Pathology
Devices Live Cell) at 37°C/5%CO2/50% relative humidity. TOTO-3
+
dead cells were quantified by taking the percentage of TOTO-3+
nuclei over total cell number.Han et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018TaqMan reverse transcription polymerase chain reaction
Primary MuSCs were cultured in RGD- or RDG-presenting hydrogels
in the growth media for 6 days and differentiated in the differentia-
tion media for an additional 5 days. Hydrogels were mechanically
homogenized, and RNA was extracted using TRIzol Reagent (Thermo
Fisher Scientific). Quality and amount of RNA were assessed using
NanoDrop (Thermo Fisher Scientific) at an absorbance at 260 and
280 nm. Complementary DNA (cDNA) was obtained using the High-
Capacity cDNAReverse TranscriptionKit, as per themanufacturer’s in-
structions (Thermo Fisher Scientific). Reverse transcription polymerase
chain reaction was performed using TaqMan assay primers (Myogenin,
Desmin, Gapdh, and b-actin probes) and TaqMan Fast Advanced
Master Mix, as per the manufacturer’s instructions (Thermo Fisher
Scientific). Ct (cycle threshold) values ofMyogenin andDesmin were
normalized to the geometric mean of Gapdh and b-actin control
genes. Fold differences were determined using 2−DDCt.
Rheological testing and mesh size estimation
Hydrogels were casted in Sigmacote-treated (Sigma-Aldrich) cylin-
drical molds consisting of a glass slide and a silicone isolator. Upon
gelation at 37°C, hydrogels were extracted and swelled in 1× PBS at
4°C overnight. Cell-containing hydrogels were synthesized and cultured
in growth media, as described above for 12 hours and 2, 3, and 5 days.
Fully swollen hydrogels were tested using a rheometer (MCR-302, Anton
Paar; CP10-2) at 37°C. Frequency sweep (100 to 0.1 rad/s)was performed
at a constant strain of 1%. G′ and G″ were determined by averaging all
data points acquired from 10 to 0.1 rad/s interval. Mesh size was esti-
mated using the following equation
x ¼ G’A
RT
 13
whereG′ is the storage modulus in Pa,A is the Avogadro’s constant, R is
the gas constant, and T is the temperature (68).
1D diffusion assay
Hydrogel was casted at one end of a glass capillary tube (outer diameter,
1 mm; inside diameter, 0.58 mm; World Precision Instruments) using
an insulin syringe. Hydrogel-containing capillary tubes were placed in a
50-ml conical tube containing 1× PBS to fully swell overnight at 4°C.
Alexa 555–labeled a-bungaroxin (8 kDa; 1:4 dilution in PBS; Thermo
Fisher Scientific) was delivered to the other free end of the hydrogel-
containing glass capillary tube. Samples were immediately placed in
the temperature and humidity-controlled stage of an epifluorescence
microscope (Zeiss Observer D1). Time-series images were acquired ev-
ery 15 min for 3 hours at 37°C. Hydrogel boundary (x = 0) was defined
by a region with an average raw intensity of 9.5 at t = 0. Change in the
average intensity was quantified from x = 0 to 200 mm over the 3-hour
assay period. To determine the diffusion coefficient (D), the data were
fitted using the solution of Fick’s second law
φðx; tÞ ¼ φ0 ⋅erfc
x
2
ffiffiffiffiffi
Dt
p
 
Cryo-injury, MuSC transplantation, and injections
Mice were anesthetized by inhalation of isoflurane. The hair over TA
muscle and gastrocnemius muscles was depilated to expose the skin.
A small incision was made through the skin and fascia to expose the11 of 14
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nloaded from
 TAmuscle. A liquid nitrogen–cooled metal probe was placed on the sur-
face of the exposed TAmuscle for 10 s to induce cryo-injury. Immediately
uponmuscle recovery, freshly isolatedMuSCswere delivered on the locus
of the injured TAmuscle in suspension (2%DBS inHBSS), in rat-tail col-
lagen type I (2.7 mg ml−1; lot # 30871G14, Culturex), or in the bio-
engineered hydrogels. For the hydrogel-mediated delivery, the cell
encapsulated hydrogelwas casted directly on the surfaced of the injured
TAmuscle. The skin incisionwas carefully sutured (Vicryl Suture, Ethicon).
All rodent survival procedures were performed using aseptic procedures.
Longitudinal bioluminescence imaging
Longitudinal bioluminescence imaging was performed using the IVIS
SpectrumCT In Vivo Imaging System (PerkinElmer). Before imaging,
mice were anesthetized by inhalation of isoflurane, and hindlimbs were
depilated. Three hundred microliters of D-luciferin (4 mg; Promega)
was injected intraperitoneally, and mice were imaged every 5 min up
to 120 min to determine the maximal signal. The maximum signal was
determined for each TA muscle and used for the subsequent analyses.
Tissue histology and immunostaining
Hindlimbswere harvested and fixed in 4%paraformaldehyde for 1 hour
at room temperature and subsequently incubated in 30% sucrose
overnight at 4°C. TA muscles were dissected and frozen in liquid
nitrogen–cooled isopentane. Frozen muscles were sectioned to 10-mm
thickness. Before antibody staining, tissue sections were blocked and
permeabilized using blocking buffer (5% BSA, 0.5% goat serum, and
0.5% Triton X-100 in 1× PBS) for 1 hour at room temperature. Tissues
for hematoxylin and eosin staining were prepared in a similar manner
without the sucrose pretreatment.
GFP fiber quantification
For quantifying number of GFP+ fibers in tissue sections, GFP channel
images of anti-GFP antibody–stained tissue sections were acquired
using an epifluorescence microscope (Zeiss Observer D1) or a confocal
microscope (Zeiss LSM 700). Images were then converted to 8-bit, and
automatic triangle-algorithm thresholds were applied using ImageJ. On
the basis of the processed binary images, GFP+ fibers were objectively
identified and scored.
Antibodies and staining reagents
The following primary and secondary antibodies were used to stain cells
and tissue sections for immunofluorescence in this study: Pax7 (1:50;
Developmental Studies Hybridoma Bank), MyoD (1:200; C-20, Santa
CruzBiotechnology),myosinheavy chain (1:200;M4276, Sigma-Aldrich),
desmin (1:200; H-76, Santa Cruz Biotechnology), Alexa Fluor 488–
conjugated anti-GFP (1:250; A-21311, Thermo Fisher Scientific), Alexa
Fluor 488 goat anti-mouse immunoglobulin G (IgG; 1:250; A-11029,
Thermo Fisher Scientific), Alexa Fluor 488 goat anti-rabbit IgG (1:250;
A-11034, Thermo Fisher Scientific), Alexa Fluor 555 goat anti-mouse
IgG (1:250; A-21422, Thermo Fisher Scientific), and Alexa Fluor 555 goat
anti-rabbit IgG (1:250; A-21424, Thermo Fisher Scientific). Alexa Fluor
555 phalloidin (1:50; Thermo Fisher Scientific) and Alexa Fluor 647 phal-
loidin (1:50; Thermo Fisher Scientific) were used to stain F-actin. Hoechst
33342 (1:1000; Thermo Fisher Scientific) and DRAQ5 (1:1000; Thermo
Fisher Scientific) were used to counterstain cell nuclei.
Statistical analyses
Sample sizes were chosen on the basis of preliminary experiments to
ensure adequate statistical power. Statistical analyses were performedHan et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018using GraphPad Prism 7. Normality of data was tested using Shapiro-
Wilk test and confirmed graphically via quantile-quantile plot. Outliers
were detected using Grubb’s test. Two-group comparisons were con-
ducted using unpaired two-tailed t test or Mann-Whitney U test based
on the data normality. For paired data, analyses were conducted using
paired two-tailed Wilcoxon or t test based on data normality. For
multiple group comparisons, one-way ANOVA with Tukey’s post hoc
tests or Kruskal-Wallis test withDunn’s post hoc tests was performed on
the basis of data normality. Two-way ANOVA with Sidak’s post hoc
tests was performed for EdU+ nuclei (%) data. Two-way repeated-
measuresANOVAwas performed on the longitudinal bioluminescence
data to compare effects of biomaterial, time, and their interactions. The
area under the curve was calculated in GraphPad Prism 7.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/4/8/eaar4008/DC1
Fig. S1. Isolated primary MuSCs are Pax7+.
Fig. S2. RGD-presenting hydrogels promote MuSC activation and proliferation.
Fig. S3. RGD-presenting hydrogels promote MuSC differentiation.
Fig. S4. Pax7/MyoD expression of MuSCs in 4 and 6% 20-kDa PEG-4MAL hydrogels.
Fig. S5. 1D diffusion assay in PEG-4MAL hydrogels.
Fig. S6. Synthetic matrix supports higher MuSC proliferation potential than collagen gel.
Table S1. List of cell-adhesive synthetic peptides and their targets.
Movie S1. Differentiated myotubes in RGD hydrogels contract in vitro.REFERENCES AND NOTES
1. A. E. Almada, A. J. Wagers, Molecular circuitry of stem cell fate in skeletal muscle
regeneration, ageing and disease. Nat. Rev. Mol. Cell Biol. 17, 267–279 (2016).
2. H. M. Blau, B. D. Cosgrove, A. T. V. Ho, The central role of muscle stem cells in regenerative
failure with aging. Nat. Med. 21, 854–862 (2015).
3. F. Oliva, A. G. Via, O. Kiritsi, C. Foti, N. Maffulli, Surgical repair of muscle laceration:
Biomechanical properties at 6 years follow-up. Muscles Ligaments Tendons J. 3, 313–317
(2014).
4. R. R. Kalyani, M. Corriere, L. Ferrucci, Age-related and disease-related muscle loss: The
effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2, 819–829
(2014).
5. P. N. Siparsky, D. T. Kirkendall, W. E. Garrett Jr., Muscle changes in aging: Understanding
sarcopenia. Sports Health 6, 36–40 (2014).
6. J. D. Cross, J. R. Ficke, J. R. Hsu, B. D. Masini, J. C. Wenke, Battlefield orthopaedic
injuries cause the majority of long-term disabilities. J. Am. Acad. Orthop. Surg. 19
(suppl. 1), S1–S7 (2011).
7. B. T. Corona, J. C. Rivera, J. G. Owens, J. C. Wenke, C. R. Rathbone, Volumetric muscle loss
leads to permanent disability following extremity trauma. J. Rehabil. Res. Dev. 52,
785–792 (2015).
8. J. F. Kragh Jr., S. J. Svoboda, J. C. Wenke, J. A. Ward, T. J. Walters, Suturing of lacerations of
skeletal muscle. J. Bone Joint Surg. Br. 87, 1303–1305 (2005).
9. B. Battiston, D. Ciclamini, J. B. Tang, Compound or specially designed flaps in the lower
extremities. Clin. Plast. Surg. 44, 287–297 (2017).
10. R. M. Garcia, D. S. Ruch, Free flap functional muscle transfers. Hand Clin. 32, 397–405
(2016).
11. R. Sambasivan, R. Yao, A. Kissenpfennig, L. Van Wittenberghe, A. Paldi, B. Gayraud-Morel,
H. Guenou, B. Malissen, S. Tajbakhsh, A. Galy, Pax7-expressing satellite cells are
indispensable for adult skeletal muscle regeneration. Development 138, 3647–3656
(2011).
12. C. Lepper, T. A. Partridge, C.-M. Fan, An absolute requirement for Pax7-positive
satellite cells in acute injury-induced skeletal muscle regeneration. Development 138,
3639–3646 (2011).
13. C. S. Fry, J. D. Lee, J. Mula, T. J. Kirby, J. R. Jackson, F. Liu, L. Yang, C. L. Mendias,
E. E. Dupont-Versteegden, J. J. McCarthy, C. A. Peterson, Inducible depletion of satellite
cells in adult, sedentary mice impairs muscle regenerative capacity without affecting
sarcopenia. Nat. Med. 21, 76–80 (2015).
14. N. A. Dumont, Y. X. Wang, J. von Maltzahn, A. Pasut, C. F. Bentzinger, C. E. Brun,
M. A. Rudnicki, Dystrophin expression in muscle stem cells regulates their polarity and
asymmetric division. Nat. Med. 21, 1455–1463 (2015).12 of 14
SC I ENCE ADVANCES | R E S EARCH ART I C L E
 o
n
 July 5, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 15. A. Sacco, F. Mourkioti, R. Tran, J. Choi, M. Llewellyn, P. Kraft, M. Shkreli, S. Delp,
J. H. Pomerantz, S. E. Artandi, H. M. Blau, Short telomeres and stem cell exhaustion model
Duchenne muscular dystrophy in mdx/mTR mice. Cell 143, 1059–1071 (2010).
16. S. Kuang, K. Kuroda, F. Le Grand, M. A. Rudnicki, Asymmetric self-renewal and
commitment of satellite stem cells in muscle. Cell 129, 999–1010 (2007).
17. A. Troy, A. B. Cadwallader, Y. Fedorov, K. Tyner, K. K. Tanaka, B. B. Olwin, Coordination of
satellite cell activation and self-renewal by Par-complex-dependent asymmetric
activation of p38a/b MAPK. Cell Stem Cell 11, 541–553 (2012).
18. D. B. Gurevich, P. D. Nguyen, A. L. Siegel, O. V. Ehrlich, C. Sonntag, J. M. N. Phan, S. Berger,
D. Ratnayake, L. Hersey, J. Berger, H. Verkade, T. E. Hall, P. D. Currie, Asymmetric
division of clonal muscle stem cells coordinates muscle regeneration in vivo. Science
353, aad9969 (2016).
19. B. D. Cosgrove, P. M. Gilbert, E. Porpiglia, F. Mourkioti, S. P. Lee, S. Y. Corbel,
M. E. Llewellyn, S. L. Delp, H. M. Blau, Rejuvenation of the muscle stem cell population
restores strength to injured aged muscles. Nat. Med. 20, 255–264 (2014).
20. L. Liu, T. H. Cheung, G. W. Charville, B. M. C. Hurgo, T. Leavitt, J. Shih, A. Brunet, T. A. Rando,
Chromatin modifications as determinants of muscle stem cell quiescence and
chronological aging. Cell Rep. 4, 189–204 (2013).
21. F. D. Price, J. von Maltzahn, C. F. Bentzinger, N. A. Dumont, H. Yin, N. C. Chang,
D. H. Wilson, J. Frenette, M. A. Rudnicki, Inhibition of JAK-STAT signaling stimulates adult
satellite cell function. Nat. Med. 20, 1174–1181 (2014).
22. P. Sousa-Victor, S. Gutarra, L. García-Prat, J. Rodriguez-Ubreva, L. Ortet, V. Ruiz-Bonilla,
M. Jardí, E. Ballestar, S. González, A. L. Serrano, E. Perdiguero, P. Muñoz-Cánoves, Geriatric
muscle stem cells switch reversible quiescence into senescence. Nature 506, 316–321
(2014).
23. J. D. Bernet, J. D. Doles, J. K. Hall, K. K. Tanaka, T. A. Carter, B. B. Olwin, p38 MAPK signaling
underlies a cell-autonomous loss of stem cell self-renewal in skeletal muscle of aged
mice. Nat. Med. 20, 265–271 (2014).
24. B. E. Pollot, S. M. Goldman, J. C. Wenke, B. T. Corona, Decellularized extracellular
matrix repair of volumetric muscle loss injury impairs adjacent bone healing in a
rat model of complex musculoskeletal trauma. J. Trauma Acute Care Surg. 81,
S184–S190 (2016).
25. J. Song, M. R. Saeman, J. De Libero, S. E. Wolf, Skeletal muscle loss is associated with TNF
mediated insufficient skeletal myogenic activation after burn. Shock 44, 479–486 (2015).
26. X. Wu, T. J. Walters, C. R. Rathbone, Skeletal muscle satellite cell activation following
cutaneous burn in rats. Burns 39, 736–744 (2013).
27. C. S. Fry, C. Porter, L. S. Sidossis, C. Nieten, P. T. Reidy, G. Hundeshagen, R. Mlcak,
B. B. Rasmussen, J. O. Lee, O. E. Suman, D. N. Herndon, C. C. Finnerty, Satellite cell
activation and apoptosis in skeletal muscle from severely burned children. J. Physiol. 594,
5223–5236 (2016).
28. M. Cerletti, S. Jurga, C. A. Witczak, M. F. Hirshman, J. L. Shadrach, L. J. Goodyear,
A. J. Wagers, Highly efficient, functional engraftment of skeletal muscle stem cells in
dystrophic muscles. Cell 134, 37–47 (2008).
29. A. Sacco, R. Doyonnas, P. Kraft, S. Vitorovic, H. M. Blau, Self-renewal and expansion of
single transplanted muscle stem cells. Nature 456, 502–506 (2008).
30. D. Montarras, J. Morgan, C. Collins, F. Relaix, S. Zaffran, A. Cumano, T. Partridge,
M. Buckingham, Direct isolation of satellite cells for skeletal muscle regeneration. Science
309, 2064–2067 (2005).
31. J. K. Hall, G. B. Banks, J. S. Chamberlain, B. B. Olwin, Prevention of muscle aging by
myofiber-associated satellite cell transplantation. Sci. Transl. Med. 2, 57ra83 (2010).
32. L. M. Marquardt, S. C. Heilshorn, Design of injectable materials to improve stem cell
transplantation. Curr. Stem Cell Rep. 2, 207–220 (2016).
33. J. R. Beauchamp, J. E. Morgan, C. N. Pagel, T. A. Partridge, Dynamics of myoblast
transplantation reveal a discrete minority of precursors with stem cell–like properties as
the myogenic source. J. Cell Biol. 144, 1113–1122 (1999).
34. M. Quarta, J. O. Brett, R. DiMarco, A. De Morree, S. C. Boutet, R. Chacon, M. C. Gibbons,
V. A. Garcia, J. Su, J. B. Shrager, S. Heilshorn, T. A. Rando, An artificial niche preserves the
quiescence of muscle stem cells and enhances their therapeutic efficacy. Nat. Biotechnol.
34, 752–759 (2016).
35. M. Quarta, M. Cromie, R. Chacon, J. Blonigan, V. Garcia, I. Akimenko, M. Hamer, P. Paine,
M. Stok, J. B. Shrager, T. A. Rando, Bioengineered constructs combined with exercise
enhance stem cell-mediated treatment of volumetric muscle loss. Nat. Commun. 8, 15613
(2017).
36. C. Borselli, C. A. Cezar, D. Shvartsman, H. H. Vandenburgh, D. J. Mooney, The role of
multifunctional delivery scaffold in the ability of cultured myoblasts to promote muscle
regeneration. Biomaterials 32, 8905–8914 (2011).
37. E. Hill, T. Boontheekul, D. J. Mooney, Designing scaffolds to enhance transplanted
myoblast survival and migration. Tissue Eng. 12, 1295–1304 (2006).
38. E. Hill, T. Boontheekul, D. J. Mooney, Regulating activation of transplanted cells controls
tissue regeneration. Proc. Natl. Acad. Sci. U.S.A. 103, 2494–2499 (2006).
39. C. A. Rossi, M. Flaibani, B. Blaauw, M. Pozzobon, E. Figallo, C. Reggiani, L. Vitiello,
N. Elvassore, P. De Coppi, In vivo tissue engineering of functional skeletal muscle byHan et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018freshly isolated satellite cells embedded in a photopolymerizable hydrogel. FASEB J. 25,
2296–2304 (2011).
40. J. P. Beier, J. Stern-Straeter, V. T. Foerster, U. Kneser, G. B. Stark, A. D. Bach, Tissue
engineering of injectable muscle: Three-dimensional myoblast-fibrin injection in the
syngeneic rat animal model. Plast. Reconstr. Surg. 118, 1113–1121 (2006).
41. G. H. Borschel, D. E. Dow, R. G. Dennis, D. L. Brown, Tissue-engineered axially vascularized
contractile skeletal muscle. Plast. Reconstr. Surg. 117, 2235–2242 (2006).
42. R. L. Page, C. Malcuit, L. Vilner, I. Vojtic, S. Shaw, E. Hedblom, J. Hu, G. D. Pins, M. W. Rolle,
T. Dominko, Restoration of skeletal muscle defects with adult human cells delivered on
fibrin microthreads. Tissue Eng. Part A 17, 2629–2640 (2011).
43. C. Fuoco, R. Rizzi, A. Biondo, E. Longa, A. Mascaro, K. Shapira-Schweitzer, O. Kossovar,
S. Benedetti, M. L. Salvatori, S. Santoleri, S. Testa, S. Bernardini, R. Bottinelli, C. Bearzi,
S. M. Cannata, D. Seliktar, G. Cossu, C. Gargioli, In vivo generation of a mature and
functional artificial skeletal muscle. EMBO Mol. Med. 7, 411–422 (2015).
44. C. Fuoco, E. Sangalli, R. Vono, S. Testa, B. Sacchetti, M. V. G. Latronico, S. Bernardini,
P. Madeddu, G. Cesareni, D. Seliktar, R. Rizzi, C. Bearzi, S. M. Cannata, G. Spinetti,
C. Gargioli, 3D hydrogel environment rejuvenates aged pericytes for skeletal muscle
tissue engineering. Front. Physiol. 5, 203 (2014).
45. C. Fuoco, M. L. Salvatori, A. Biondo, K. Shapira-Schweitzer, S. Santoleri, S. Antonini,
S. Bernardini, F. S. Tedesco, S. Cannata, D. Seliktar, G. Cossu, C. Gargioli, Injectable
polyethylene glycol-fibrinogen hydrogel adjuvant improves survival and differentiation
of transplanted mesoangioblasts in acute and chronic skeletal-muscle degeneration.
Skelet. Muscle 2, 24 (2012).
46. W. M. Han, Y. C. Jang, A. J. García, Engineered matrices for skeletal muscle satellite cell
engraftment and function. Matrix Biol. 60–61, 96–109 (2017).
47. E. A. Phelps, D. M. Headen, W. R. Taylor, P. M. Thulé, A. J. García, Vasculogenic bio-
synthetic hydrogel for enhancement of pancreatic islet engraftment and function in type
1 diabetes. Biomaterials 34, 4602–4611 (2013).
48. J. D. Weaver, D. M. Headen, J. Aquart, C. T. Johnson, L. D. Shea, H. Shirwan, A. J. García,
Vasculogenic hydrogel enhances islet survival, engraftment, and function in leading
extrahepatic sites. Sci. Adv. 3, e1700184 (2017).
49. A. S. Salimath, A. J. García, Biofunctional hydrogels for skeletal muscle constructs. J. Tissue
Eng. Regen. Med. 10, 967–976 (2014).
50. E. A. Phelps, N. O. Enemchukwu, V. F. Fiore, J. C. Sy, N. Murthy, T. A. Sulchek, T. H. Barker,
A. J. García, Maleimide cross-linked bioactive PEG hydrogel exhibits improved reaction
kinetics and cross-linking for cell encapsulation and in situ delivery. Adv. Mater. 24, 64–70
(2012).
51. N. O. Enemchukwu, R. Cruz-Acuña, T. Bongiorno, C. T. Johnson, J. R. García, T. Sulchek,
A. J. García, Synthetic matrices reveal contributions of ECM biophysical and biochemical
properties to epithelial morphogenesis. J. Cell Biol. 212, 113–124 (2016).
52. L. Lukjanenko, M. J. Jung, N. Hegde, C. Perruisseau-Carrier, E. Migliavacca, M. Rozo,
S. Karaz, G. Jacot, M. Schmidt, L. Li, S. Metairon, F. Raymond, U. Lee, F. Sizzano,
D. H. Wilson, N. A. Dumont, A. Palini, R. Fässler, P. Steiner, P. Descombes, M. A. Rudnicki,
C.-M. Fan, J. von Maltzahn, J. N. Feige, C. F. Bentzinger, Loss of fibronectin from the aged
stem cell niche affects the regenerative capacity of skeletal muscle in mice. Nat. Med. 22,
897–905 (2016).
53. A. L. Siegel, K. Atchison, K. E. Fisher, G. E. Davis, D. D. W. Cornelison, 3D timelapse analysis
of muscle satellite cell motility. Stem Cells 27, 2527–2538 (2009).
54. H. Liu, A. Niu, S.-E. Chen, Y.-P. Li, b3-integrin mediates satellite cell differentiation in
regenerating mouse muscle. FASEB J. 25, 1914–1921 (2011).
55. P. M. Gilbert, K. L. Havenstrite, K. E. G. Magnusson, A. Sacco, N. A. Leonardi, P. Kraft,
N. K. Nguyen, S. Thrun, M. P. Lutolf, H. M. Blau, Substrate elasticity regulates skeletal
muscle stem cell self-renewal in culture. Science 329, 1078–1081 (2010).
56. P. Lu, K. Takai, V. M. Weaver, Z. Werb, Extracellular matrix degradation and remodeling in
development and disease. Cold Spring Harb. Perspect. Biol. 3, a005058 (2011).
57. D. Hardy, A. Besnard, M. Latil, G. Jouvion, D. Briand, C. Thépenier, Q. Pascal, A. Guguin,
B. Gayraud-Morel, J.-M. Cavaillon, S. Tajbakhsh, P. Rocheteau, F. Chrétien, Comparative
study of injury models for studying muscle regeneration in mice. PLOS ONE 11, e0147198
(2016).
58. G. Le, D. A. Lowe, M. Kyba, Freeze injury of the tibialis anterior muscle. Methods Mol. Biol.
1460, 33–41 (2016).
59. C. F. Bentzinger, Y. X. Wang, J. von Maltzahn, V. D. Soleimani, H. Yin, M. A. Rudnicki,
Fibronectin regulates Wnt7a signaling and satellite cell expansion. Cell Stem Cell 12,
75–87 (2013).
60. M. Rozo, L. Li, C.-M. Fan, Targeting b1-integrin signaling enhances regeneration in aged
and dystrophic muscle in mice. Nat. Med. 22, 889–896 (2016).
61. E. Ruoslahti, RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol.
12, 697–715 (1996).
62. J. A. Rowley, D. J. Mooney, Alginate type and RGD density control myoblast
phenotype. J. Biomed. Mater. Res. 60, 217–223 (2002).
63. R. Darabi, R. W. Arpke, S. Irion, J. T. Dimos, M. Grskovic, M. Kyba, R. C. R. Perlingeiro,
Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve13 of 14
SC I ENCE ADVANCES | R E S EARCH ART I C L E
D
ocontractility upon transplantation in dystrophic mice. Cell Stem Cell 10, 610–619
(2012).
64. E. Sleep, B. D. Cosgrove, M. T. McClendon, A. T. Preslar, C. H. Chen, M. H. Sangji,
C. M. R. Pérez, R. D. Haynes, T. J. Meade, H. M. Blau, S. I. Stupp, Injectable biomimetic
liquid crystalline scaffolds enhance muscle stem cell transplantation. Proc. Natl. Acad.
Sci. U.S.A. 114, E7919–E7928 (2017).
65. L. Boldrin, A. Neal, P. S. Zammit, F. Muntoni, J. E. Morgan, Donor satellite cell engraftment
is significantly augmented when the host niche is preserved and endogenous satellite
cells are incapacitated. Stem Cells 30, 1971–1984 (2012).
66. J. G. Tidball, Regulation of muscle growth and regeneration by the immune system.
Nat. Rev. Immunol. 17, 165–178 (2017).
67. A. E. Carpenter, T. R. Jones, M. R. Lamprecht, C. Clarke, I. H. Kang, O. Friman, D. A. Guertin,
J. H. Chang, R. A. Lindquist, J. Moffat, P. Golland, D. M. Sabatini, CellProfiler: Image analysis
software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).
68. M. Rubinstein, R. H. Colby, Polymer Physics (Oxford Univ. Press, 2003).
Acknowledgments: We thank the Physiological Research Laboratory and core facilities at the
Parker H. Petit Institute for Bioengineering and Bioscience at the Georgia Institute of
Technology for the use of shared equipment, services, and expertize. Finally, we thank
A. Wagers for providing the C57Bl/6-b-actin-EGFP mice. This research was conducted while
W.M.H. was a Glenn/American Federation of Aging Research Postdoctoral Fellow. Funding:
Research reported in this publication was supported by the National Institute of Arthritis
and Musculoskeletal and Skin Diseases of the NIH under award numbers R21AR072287Han et al., Sci. Adv. 2018;4 : eaar4008 15 August 2018(to Y.C.J.) and R01AR062368 (to A.J.G.). The content is solely the responsibility of the authors
and does not necessarily represent the official views of the NIH. This work was also funded
by the Parker H. Petit Institute for Bioengineering and Bioscience Seed Grant Program (to
A.J.G. and Y.C.J.). Author contributions: W.M.H., A.J.G., and Y.C.J. designed the study, analyzed
the data, and wrote the manuscript. W.M.H., S.E.A., M.M., D.B., S.A.N., I.F.A., A.P.P., and E.S.
conducted the experiments, analyzed the data, and reviewed the manuscript. E.S., S.A.N., and
Y.C.J. generated and maintained the animals used in this study. Competing interests: The
authors declare that they have no competing interests. Data and materials availability: All
data needed to evaluate the conclusions in the paper are present in the paper and/or the
Supplementary Materials. Components for hydrogels may be provided by the Georgia Institute
of Technology pending scientific review and a completed material transfer agreement.
Requests for these materials should be submitted to A.J.G. Additional data related to this
paper may be requested from the authors.
Submitted 3 November 2017
Accepted 11 July 2018
Published 15 August 2018
10.1126/sciadv.aar4008
Citation: W. M. Han, S. E. Anderson, M. Mohiuddin, D. Barros, S. A. Nakhai, E. Shin, I. F. Amaral,
A. P. Pêgo, A. J. García, Y. C. Jang, Synthetic matrix enhances transplanted satellite cell
engraftment in dystrophic and aged skeletal muscle with comorbid trauma. Sci. Adv. 4,
eaar4008 (2018).w
n14 of 14
 o
n
 July 5, 2019
http://advances.sciencem
ag.org/
loaded from
 
skeletal muscle with comorbid trauma
Synthetic matrix enhances transplanted satellite cell engraftment in dystrophic and aged
Amaral, Ana Paula Pêgo, Andrés J. García and Young C. Jang
Woojin M. Han, Shannon E. Anderson, Mahir Mohiuddin, Daniela Barros, Shadi A. Nakhai, Eunjung Shin, Isabel Freitas
DOI: 10.1126/sciadv.aar4008
 (8), eaar4008.4Sci Adv 
ARTICLE TOOLS http://advances.sciencemag.org/content/4/8/eaar4008
MATERIALS
SUPPLEMENTARY http://advances.sciencemag.org/content/suppl/2018/08/13/4.8.eaar4008.DC1
REFERENCES
http://advances.sciencemag.org/content/4/8/eaar4008#BIBL
This article cites 67 articles, 13 of which you can access for free
PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions
Terms of ServiceUse of this article is subject to the 
registered trademark of AAAS.
is aScience Advances Association for the Advancement of Science. No claim to original U.S. Government Works. The title 
York Avenue NW, Washington, DC 20005. 2017 © The Authors, some rights reserved; exclusive licensee American 
(ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 NewScience Advances 
 o
n
 July 5, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
